Matinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203
BEDMINSTER, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the publication of […]